Evidence map›Paper›PMID 42842564›Full record

ArticlePloS one2026

Investigating the anticancer potential of phytochemicals from the mangrove Rhizophora mucronata as inhibitors of lung cancer-associated proteins: Insights from multiscale computational and in silico analyses.

Zena Abdul-Ameer Mahdi, Batool Shakir Abed AlmjalawI, Mollah Naimuzzaman, Md Mahabub Hasan, Ajoy Kumer, Farah Tareq Al-Alaq, Hussein O M Al-Dahmoshi, Faizur Rahman, Md Fayez Al-Hakim Khan, Noor S K Al-Khafaji and 1 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zena Abdul-Ameer MahdiDepartment of Medical Physics, College of Applied Medical Sciences, University of Kerbala, Karbala, Iraq.
Batool Shakir Abed AlmjalawIMinistry of Education, General Directorate of Education in Kerbala, Iraq.
Mollah NaimuzzamanDepartment of Agroforestry and Environmental Science, Sylhet Agricultural University, Sylhet, Bangladesh.
Md Mahabub HasanCollege of Agricultural Sciences, IUBAT-International University of Business Agriculture and Technology, Dhaka, Bangladesh.
Ajoy KumerDepartment of General Medicine, Saveetha Institute of Medical and Technical Sciences in Saveetha Medical College and Hospital, Chennai, India.ORCID https://orcid.org/0000-0001-5136-6166
Farah Tareq Al-AlaqDepartment of Biology, College of Science, University of Babylon, Babylon, Iraq.
Hussein O M Al-DahmoshiDepartment of Biology, College of Science, University of Babylon, Babylon, Iraq.
Faizur RahmanCollege of Agricultural Sciences, IUBAT-International University of Business Agriculture and Technology, Dhaka, Bangladesh.
Md Fayez Al-Hakim KhanCollege of Agricultural Sciences, IUBAT-International University of Business Agriculture and Technology, Dhaka, Bangladesh.
Noor S K Al-KhafajiDepartment of Biology, College of Science, University of Babylon, Babylon, Iraq.
Sarah Alwan Malik Al-YasiriDepartment of Environmental Health, College of Applied Medical Sciences, University of Kerbala, Karbala, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide, with a five-year survival rate of approximately 20-25% despite advances in targeted therapy and immunotherapy. There is a continuous need for novel, low-toxicity compounds capable of modulating key oncogenic pathways in non-small cell lung cancer (NSCLC). Mangrove ecosystems are rich reservoirs of bioactive phytochemicals, yet the inhibitory potential of compounds from Rhizophora mucronata against validated lung cancer-associated proteins has not been systematically explored using multi-scale computational approaches. This study employed an integrated computational pipeline to evaluate 14 phytochemicals from R. mucronata. Density Functional Theory (DFT) calculations at the B3LYP/6-31G* level were performed to characterize electronic properties of the ligands. Molecular docking studies were conducted using both AutoDock Vina (PyRx) and Schrödinger Glide against the Keap1 Kelch domain (PDB 1X2J) and the YEATS2 YEATS domain (PDB 5XNV). Top-ranked complexes were subjected to 100-ns molecular dynamics (MD) simulations in Desmond, and pharmacokinetic and toxicity profiles were predicted using SwissADME and pkCSM. Among the screened compounds, ligand L10 (cyclohexane-1,2,3,4,5,6-hexaol) exhibited the smallest HOMO-LUMO energy gap (0.36 eV), favorable binding affinities (Glide score of -7.789 kcal/mol against 1X2J), multiple hydrogen-bonding interactions, and stable complex behavior during MD simulations (Cα RMSD < 3 Å). Several other ligands (L02, L05, and L07) also displayed promising profiles. Most compounds complied with Lipinski's rule of five and showed acceptable predicted ADMET properties. These preliminary findings suggest that Rhizophora mucronate -derived phytochemicals, particularly L10, are promising candidates for further experimental evaluation as modulators of Keap1 and YEATS2 in lung cancer. This study provides a computational framework for prioritizing natural product leads from mangrove species for subsequent in vitro and in vivo validation.

Indexed as

Antineoplastic Agents, PhytogenicCarcinoma, Non-Small-Cell LungKelch-Like ECH-Associated Protein 1Lung NeoplasmsPhytochemicalsRhizophoraceaeComputer SimulationHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationAntineoplastic Agents, PhytogenicKEAP1 protein, humanKelch-Like ECH-Associated Protein 1LigandsPhytochemicals

Identifiers

PMID42842564
PMCPMC13645060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.